The antibodies and chemicals were obtained from the following resources;
anti-PARP (#556362),
anti-XIAP (#610716),
anti-FADD (#610399),
anti-RIP1 (#610459),
anti-p53 (#554147) and
anti-p21 (#556430) antibodies (BD Biosciences, San Diego, CA, USA);
anti-caspase-3 (#9662),
anti-caspase-8 (#9746),
anti-caspase-9 (#9508) and
anti-Bid (#2002) antibodies (Cell signalling Technology, Beverly, MA, USA); anti-caspase-10 (M059-3) antibody (MBL, WOBURN, MA, USA); anti-Bcl-X
S/L (sc-271121), anti-survivin (sc-17779), anti-TRAF2 (sc-876), anti-GFP (sc-9996) and
anti-HA (sc-805) antibodies (Santa Cruz, CA, USA); anti-c-FLIP (ALX-804-961) antibody (Enzo Life Sciences, Farmingdale, NY, USA); anti-cIAP1/2 (#07-759) antibody (Upstate Biotech, Waltham, MA, USA); anti-DR5 (#ab181846) antibody (Abcam, Cambridge, UK); anti-DR4 (NB100-56528) antibody (Novus, Centennial, CO, USA); anti-TurboGFP (PA5-22688) antibody (Thermo scientific, Waltham, Massachusetts, USA); anti-actin (A2066), anti-flag (F3165, 1:2,000 dilution) antibodies (Sigma-Aldrich, St. Louis, MO, USA). the pan caspase inhibitor Z-VAD-FMK, MG-132, TPCA-1 (Calbiochem, San Diego, CA, USA);
recombinant TNF (R & D Systems, Minneapolis, MN, USA);
recombinant human TRAIL/Apo2 ligand (Peprotech, Rocky Hill, NJ, USA).
Lee S.R., Quan K.T., Byun H.S., Park I., Kang K., Piao X., Ju E., Ro H., Na M, & Hur G.M. (2019). Accelerated degradation of cFLIPL and sensitization of the TRAIL DISC-mediated apoptotic cascade by pinoresinol, a lignan isolated from Rubia philippinensis. Scientific Reports, 9, 13505.